Get the Stockscreener App
1.98
8.33%
-0.18
After Hours:
1.96
-0.02
-1.01%
Gossamer Bio Inc stock is traded at $1.98, with a volume of 3.96M.
It is down -8.33% in the last 24 hours and up +59.68% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$2.16
Open:
$2.18
24h Volume:
3.96M
Relative Volume:
1.68
Market Cap:
$450.06M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-1.4887
EPS:
-1.33
Net Cash Flow:
$-159.16M
1W Performance:
-4.81%
1M Performance:
+59.68%
6M Performance:
+78.38%
1Y Performance:
+137.70%
1-Day Range:
$1.92
$2.21
1-Week Range:
$1.91
$2.23
52-Week Range:
$0.6617
$2.23
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
1.98 | 490.97M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Gossamer Bio 2025 Q2 Earnings Sharp Net Loss Amid Revenue Drop - AInvest
Gossamer Bio shares fall 7.41% premarket despite beating earnings expectations. - AInvest
Gossamer Bio Inc. Exceeds Q2 Expectations Despite LossNews and Statistics - IndexBox
Gossamer Bio: Q2 Earnings Snapshot - New Haven Register
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Gossamer Bio earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Gossamer Bio shares rise 1.39% after-hours despite Q2 revenue drop of 88%. - AInvest
Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
GOSS Achieves Strong Q2 Revenue and Prepares for Commercial Expa - GuruFocus
Gossamer Bio Reports Q2 Revenue Drop of 88% - AInvest
Gossamer Bio's 390-Patient PAH Trial Nears Crucial February Readout, $213M Cash Runway - Stock Titan
Will Gossamer Bio Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser
Real time scanner hits for Gossamer Bio Inc. explainedWeekly Gain Forecast with Momentum Indicators - Newser
How Gossamer Bio Inc. stock performs during market volatilityRSI and MACD Signal Summary with Trends - Newser
Can Gossamer Bio Inc. rally from current levelsStrategy Builder for Growth Focused Traders - Newser
Why is Gossamer Bio Inc. stock attracting strong analyst attentionExponentially increasing returns - Jammu Links News
Custom strategy builders for tracking Gossamer Bio Inc.Market Liquidity and Price Flow Analysis - Newser
Published on: 2025-08-04 06:30:01 - beatles.ru
Is Gossamer Bio Inc. forming a reversal patternReal-Time Investment Signal Forecast with AI - Newser
How volatile is Gossamer Bio Inc. stock compared to the marketCapitalize on market momentum for maximum gains - Jammu Links News
Why Gossamer Bio Inc. is moving todayStock Market Watch with Smart Filters - Newser
Why Gossamer Bio Inc. stock attracts strong analyst attentionLong-Term Allocation Strategy Summary Breakdown - Newser
What are the latest earnings results for Gossamer Bio Inc.Capitalize on fast-moving stock trends - Jammu Links News
What is the dividend policy of Gossamer Bio Inc. stockCapitalize on high-yield stocks early - Jammu Links News
When is Gossamer Bio Inc. stock expected to show significant growthFree Expert Stock Watchlist - Jammu Links News
How strong is Gossamer Bio Inc. company’s balance sheetUnlock daily trading alerts for profits - Jammu Links News
Is it the right time to buy Gossamer Bio Inc. stockCapitalize on stocks with high profit margins - Jammu Links News
How does Gossamer Bio Inc. compare to its industry peersInvest smarter with real-time trading alerts - Jammu Links News
Does Gossamer Bio Inc. stock perform well during market downturnsAchieve breakthrough profits with smart strategies - Jammu Links News
Is Gossamer Bio Inc. stock poised for growthFree Fast Gaining Stock Screener Report - Newser
Gossamer Bio Inc. Stock Analysis and ForecastAmplify your gains with low-risk picks - Jammu Links News
What institutional investors are buying Gossamer Bio Inc. stockBuild a portfolio that stands the test of time - Jammu Links News
How many analysts rate Gossamer Bio Inc. as a “Buy”Discover market opportunities others miss - Jammu Links News
What catalysts could drive Gossamer Bio Inc. stock higher in 2025Double-digit growth - Jammu Links News
What are analysts’ price targets for Gossamer Bio Inc. in the next 12 monthsFree Stock Selection - Jammu Links News
Regression analysis insights on Gossamer Bio Inc. performanceFree Trade Ready Stock Watch for Short Term - Newser
Is this a good reentry point in Gossamer Bio Inc.Smart Entry Signals for Active Traders - Newser
Institutional scanner results for Gossamer Bio Inc.Free Smart Trade Plans With Risk Protection - Newser
Institutional Investors Have a Lot Riding on Gossamer Bio, Inc. (NASDAQ:GOSS) With 63% Ownership - 富途牛牛
What momentum shifts mean for Gossamer Bio Inc.Stock Price Prediction Using AI Tools - Newser
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):